口服湿疹药物或推动股价翻倍——高盛看多Corvus制药

口服湿疹药物或推动股价翻倍——高盛看多Corvus制药

This biopharma stock could more than double on oral eczema treatment, Goldman Sachs says

Corvus Pharmaceuticals is developing an oral drug for a common skin condition that could push its shares a lot higher, a…